Raloxifene reduces risk of vertebral fractures and breast cancer in postmenopausal women regardless of prior hormone therapy

Journal of Family Practice

Volumn 53, Issue 10, 2004, Pages 789-796

  Johnell, Olof ^a   Cauley, Jane A ^b   Kulkarni, Pandurang M ^c   Wong, Mayme ^c   Stock, John L ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; RALOXIFENE; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BREAST CANCER; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; RISK REDUCTION; VERTEBRA FRACTURE;

ADULT; AGED; BONE DENSITY; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; RISK; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SPINAL FRACTURES;

EID: 5344249408     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999; 353:571-580.
2. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016-1037.
3. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
4. Bren L. The estrogen and progestin dilemma: New advice, labeling and guidelines. FDA Consumer 2003; 37:10-11.
5. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004; 140:184-188.
6. Gallagher JC, Rapuri PB, Haynatzki G, Detter JR. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J Clin Endocrinol Metab 2002; 87:4914-4923.
7. Tremollieres FA, Pouilles JM, Ribot C. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos Int 2001; 12:385-390.
8. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 2003; 348:618-629.
9. Maricic M, Gluck O. Review of raloxifene and its clinical applications in osteoporosis. Expert Opin Pharmacother 2002; 3:767-775.
10. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87:3609-3617.
11. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 1999; 282:637-645.
12. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8:1137-1148.
13. Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002; 162:1140-1143.
14. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287:847-857.
15. Mosca L, Barrett-Connor E, Wenger NK, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 2001; 88:392-395.
16. Cauley J, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year Results from the MORE Trial. Breast Cancer Res Treat 2001; 65:125-134.
17. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003; 348:645-650.
18. Cauley J, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995; 122:9-16.
19. Greendale GA, Espeland M, Slone S, Marcus R, Barrett-Connor E. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Intern Med 2002; 162:665-672.
20. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA 2002; 288:49-57.
21. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998; 8:468-489.